Stock Events

Stock Events

NeuroPace 

$15.30
5
+$0.00+0% 19:36 Today

Statistics

Day High
15.4
Day Low
15.29
52W High
19.6
52W Low
7.56
Volume
944
Avg. Volume
-
Mkt Cap
521.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.27
-0.22
-0.16
-0.11
Expected EPS
-0.217854
Actual EPS
N/A

Financials

-21.47%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
99.99MRevenue
-21.47MNet Income

Analyst Ratings

21.00Average Price Target
The highest estimate is 22.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NPCE. It's not an investment recommendation.
Microsoft
4
MSFT
Tesla
4
TSLA
Amazon
4
AMZN
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap107.36B
Medtronic offers a range of neurostimulation devices that compete directly with NeuroPace's RNS System for epilepsy treatment.
Abbott Laboratories
ABT
Mkt Cap163.61B
Abbott Laboratories provides various neuromodulation devices, including those for epilepsy, which competes with NeuroPace's solutions.
LivaNova
LIVN
Mkt Cap4.54B
LivaNova operates in the neuromodulation space with its VNS Therapy System, which is used for the treatment of drug-resistant epilepsy and directly competes with NeuroPace's offerings.
Smith & Nephew
SNN
Mkt Cap12.94B
Smith & Nephew offers advanced medical devices in various areas, including neuromodulation, competing in the broader market that NeuroPace targets.
Boston Scientific
BSX
Mkt Cap66.54B
Boston Scientific Corporation designs and manufactures medical devices, including neuromodulation products that could be used in applications similar to those of NeuroPace.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, through its extensive pharmaceutical solutions, offers medications for epilepsy, competing in the broader epilepsy treatment market against NeuroPace's device-focused approach.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. produces several drugs for neurological conditions, including epilepsy, offering an alternative to NeuroPace's neuromodulation devices.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers neurosurgical and neuromodulation products that could compete with NeuroPace's epilepsy treatment solutions.
Zoetis
ZTS
Mkt Cap31.68B
Zoetis, primarily focused on animal health, including neurological conditions in animals, represents a less direct form of competition in the broader neurology market.

About

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Show more...
CEO
Mr. Joel D. Becker
Employees
220
Country
United States
ISIN
US6412881053

Listings

XNAS
US
NPCE
BOATS
BOATS
NPCE.BOATS

0 Comments

Share your thoughts

FAQ

What is NeuroPace stock price today?▼
The current price of NPCE is $15.30 USD — it has increased by +0% in the past 24 hours. Watch NeuroPace stock price performance more closely on the chart.
What is NeuroPace stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NeuroPace stocks are traded under the ticker NPCE.
Is NeuroPace stock price growing?▼
NPCE stock has fallen by -1% compared to the previous week, the month change is a -7.07% fall, over the last year NeuroPace has showed a +75.11% increase.
What is NeuroPace market cap?▼
Today NeuroPace has the market capitalization of 521.63M
When is the next NeuroPace earnings date?▼
NeuroPace is going to release the next earnings report on August 06, 2026.
What were NeuroPace earnings last quarter?▼
NPCE earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.23 USD resulting in a +12.95% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NeuroPace revenue for the last year?▼
NeuroPace revenue for the last year amounts to 99.99M USD.
What is NeuroPace net income for the last year?▼
NPCE net income for the last year is -21.47M USD.
How many employees does NeuroPace have?▼
As of July 28, 2026, the company has 220 employees.
In which sector is NeuroPace located?▼
NeuroPace operates in the Health & Wellness sector.
When did NeuroPace complete a stock split?▼
NeuroPace has not had any recent stock splits.
Where is NeuroPace headquartered?▼
NeuroPace is headquartered in Mountain View, United States.